Ziaee Seyyed Mohyeddin, Tabeshmehr Parisa, Haider Khawaja Husnain, Farrokhi Majidreza, Shariat Abdolhamid, Amiri Atena, Hosseini Seyed Mojtaba
Student Research Committee, Medical Faculty, Shiraz University of Medical Sciences, Shiraz, Iran.
Stem Cell Laboratory, Department of Anatomy, Medical Faculty, Shiraz University of Medical Sciences, Shiraz, Iran.
Stem Cell Investig. 2017 Apr 14;4:29. doi: 10.21037/sci.2017.03.10. eCollection 2017.
Despite encouraging data in terms of neurological outcome, stem cell based therapy for ischemic stroke in experimental models and human patients is still hampered by multiple as yet un-optimized variables, i.e., time of intervention, that significantly influence the prognosis. The aim of the present study was to delineate the optimum time for neural stem cells (NSCs) transplantation after ischemic stroke.
The NSCs were isolated from 14 days embryo rat ganglion eminence and were cultured in NSA medium (neurobasal medium, 2% B27, 1% N2, bFGF 10 ng/mL, EGF 20 ng/mL and 1% pen/strep). The cells were characterized for tri-lineage differentiation by immunocytochemistry for tubulin-III, Olig2 and GFAP expression for neurons, oligodendrocytes and astrocyte respectively. The NSCs at passage 3 were injected intraventricularly in a rodent model of middle-cerebral artery occlusion (MCAO) on stipulated time points of 1 & 12 h, and 1, 3, 5 and 7 days after ischemic stroke. The animals were euthanized on day 28 after their respective treatment.
dUTP nick end labeling (TUNEL) assay and Caspase assay showed significantly reduced number of apoptotic cells on day 3 treated animals as compared to the other treatment groups of animals. The neurological outcome showed that the group which received NSCs 3 days after brain ischemia had the best neurological performance.
The optimum time for NSCs transplantation was day 3 after ischemic stroke in terms of attenuation of ischemic zone expansion and better preserved neurological performance.
尽管在神经学预后方面有令人鼓舞的数据,但在实验模型和人类患者中,基于干细胞的缺血性中风治疗仍受到多个尚未优化的变量的阻碍,即干预时间,这对预后有显著影响。本研究的目的是确定缺血性中风后神经干细胞(NSCs)移植的最佳时间。
从14天龄胚胎大鼠神经节隆起中分离出神经干细胞,并在NSA培养基(神经基础培养基、2%B27、1%N2、10 ng/mL碱性成纤维细胞生长因子、20 ng/mL表皮生长因子和1%青霉素/链霉素)中培养。通过免疫细胞化学分别检测微管蛋白-III、少突胶质细胞转录因子2和胶质纤维酸性蛋白的表达,对细胞进行三系分化鉴定,分别代表神经元、少突胶质细胞和星形胶质细胞。将第3代神经干细胞在缺血性中风后1小时和12小时、1天、3天、5天和7天的规定时间点,经脑室注射到大脑中动脉闭塞(MCAO)的啮齿动物模型中。在各自治疗后第28天对动物实施安乐死。
脱氧尿苷三磷酸缺口末端标记(TUNEL)检测和半胱天冬酶检测显示,与其他治疗组动物相比,第3天治疗的动物凋亡细胞数量显著减少。神经学结果表明,脑缺血后3天接受神经干细胞治疗的组神经学表现最佳。
就减轻缺血区扩展和更好地保留神经学表现而言,神经干细胞移植的最佳时间是缺血性中风后第3天。